grant
saveMAPP BIOPHARMACEUTICAL, INC. — Development of highly potent human monoclonal for RSV immunoprophylaxis
September 24, 2025updated 5mo ago
community read0 votes
AI grant. $993,353. PI: Ellen Monson
view source ↗Data sources
last refreshed 5mo ago
Found something off?
comments(0)
5-min edit window · permanent after that